Trematode Infections: Clinical Trials

11 trials for Trematode Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 unknown. 11 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Completed 10, Unknown 1
Phase 22Completed 1, Unknown 1

Follow Trematode Infections: new trials by email Literature Review of Trematode Infections trials Research Report on Trematode Infections

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of the rSm-p80 + GLA-SE (SchistoShield®) Candidate Vaccine in Healthy Adults in Burkina Faso and Madagascar
rSm-p80 + GLA-SE - Schistosomiasis
Phase 1CompletedInternational Vaccine Institute1202023-11-172026-04-29
Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults
Sm-p80, Sm-p80 + GLA-SE - Schistosomiasis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)452022-05-232025-07-14
Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults
Sm-TSP-2/Alhydrogel® vaccine, Sm-TSP-2/Alhydrogel® vaccine plus AP 10-701, ENGERIX-B Hepatitis B Vaccine - Schistosomiasis, Schistosoma Mansoni
Phase 1 / Phase 2CompletedBaylor College of Medicine2902019-10-072025-11-04
A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults
GLA-AF, Hepatitis B Virus Vaccine (Recombinant), Sm-TSP-2/Alhydrogel - Schistosomiasis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)602018-05-202021-02-02
Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers
Oxfendazole - Helminthic Infection
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)362017-05-122019-12-17
A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults
Placebo, Sm-TSP-2/Alhydrogel, Sm-TSP-2/Alhydrogel/GLA-AF - Schistosomiasis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)722015-02-042017-06-26
Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis
parasitological diagnostics (coproscopy), Nitazoxanide 500Mg Oral Tablet, Mesalazine 250Mg Tablet and nitazoxanide 500Mg Oral Tablet - Ulcerative Colitis, Ulcerative Colitis Exacerbation
Phase 1 / Phase 2UnknownResearch Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan3002015-01-012023-03-03
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
DNA, AIDSVAX B/E - HIV/AIDS
Phase 1CompletedEuroVacc Foundation722014-09-012016-01-22
Praziquantel-Pharmacokinetic Study
Praziquantel - Schistosomiasis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)472012-01-012019-01-18
Study to Evaluate the Safety of the Vaccine Prepared sm14 Against Schistosomiasis
sm14 antigen plus adjuvant GLA - Schistosomiasis
Phase 1CompletedOswaldo Cruz Foundation202011-03-012016-08-10
Clinical Trial of Bilhvax,a Vaccine Candidate Against Schistosomiasis
rSh28GST - Schistosomiasis, Bilharziasis
Phase 1CompletedUniversity Hospital, Lille241998-09-012013-08-27

Narrower conditions

Schistosomiasis (8)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Colitis, Ulcerative (1)  ·  Protozoan Infections (1)  ·  Schistosomiasis haematobia (1)

Broader conditions

Helminthiasis (11)  ·  Infections (11)  ·  Parasitic Diseases (11)  ·  Vector Borne Diseases (8)  ·  Urogenital Diseases (2)  ·  Blood-Borne Infections (1)  ·  Colitis (1)  ·  Colonic Diseases (1)  ·  Communicable Diseases (1)  ·  Digestive System Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Gastroenteritis (1)  ·  Gastrointestinal Diseases (1)

Interventions

AIDSVAX B-E (1)  ·  DNA (1)  ·  GLA-AF adjuvant (1)  ·  Hepatitis B Vaccines (1)  ·  Mesalamine (1)  ·  Praziquantel (1)  ·  Tablets (1)  ·  nitazoxanide (1)  ·  oxfendazole (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (5)  ·  Baylor College of Medicine (1)  ·  EuroVacc Foundation (1)  ·  International Vaccine Institute (1)  ·  Oswaldo Cruz Foundation (1)  ·  Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan (1)  ·  University Hospital, Lille (1)

Countries

United States (3)  ·  Brazil (2)  ·  Uganda (2)  ·  Burkina Faso (1)  ·  France (1)  ·  Madagascar (1)  ·  Philippines (1)

Top investigators

Florian Marks (1)  ·  Hannah Kibuuka, MD (1)  ·  Marilia S Oliveira, MD, MsC (1)  ·  Pontiano Kaleebu (1)

Results publications

PMID 22802974, PMID 26571311, PMID 32816721, PMID 33188747, PMID 36996185, PMID 41285840

NIH funding

5UM1AI148373-03 (1), U01AI066050 (1)